Form 4: Stoke Therapeutics CEO Exercises Stock Options, Reports Beneficial Ownership Changes
SEC Form 4 Filing
CEO of Stoke Therapeutics, Edward M. Kaye, reports exercising stock options and changes in beneficial ownership of company stock.
Summary
- On December 30, 2024, Edward M. Kaye, CEO of Stoke Therapeutics, exercised employee stock options to acquire 35,000 shares of common stock at a price of $0.6 per share.
- This transaction was reported on a Form 4 filing with the SEC.
- Following the transaction, Kaye directly owns 96,885 shares of common stock and 567,801 derivative securities.
- The exercised options became fully vested as of October 17, 2022, and expire on April 02, 2028.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock option exercise.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in outstanding shares.
- The exercise of stock options is part of the CEO's compensation package.
Key Dates
| Date | Description |
|---|---|
| 10/17/2022 | Employee stock options became fully vested |
| 12/30/2024 | Date of transaction: CEO exercised stock options |
| 01/02/2025 | Date of report filing |
| 04/02/2028 | Expiration date of the employee stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.